Johnson & Johnson will begin marketing four of its prescription drugs on the Trump administration's TrumpRx website on Friday, doubling the number of drugs on the platform.
The move was first reported by CBS News and follows a voluntary agreement between the pharmaceutical giant and the Trump administration.
The four drugs include the type 2 diabetes treatments metformin and Invokana, as well as the blood thinner Xarelto. The company has also committed to a $55 billion investment in US-based research and production in Pennsylvania and North Carolina.
This partnership provides a new sales channel for Johnson & Johnson but also carries brand risk. The TrumpRx platform is designed for uninsured patients, a segment that typically pays full list price.
The deal with Johnson & Johnson follows a similar agreement announced Thursday between the Trump administration and drugmaker Regeneron. Regeneron agreed to lower the prices of its drugs on Medicaid and sell its cholesterol drug Praluent for $225 on the TrumpRx site. As part of its deal, Regeneron committed to spending $27 billion on research, development, and manufacturing in the U.S.
Regeneron also announced that its new gene therapy for a rare form of congenital hearing loss, Otarmeni, would be available at no charge to clinically eligible individuals in the U.S. after receiving expedited approval from the Food and Drug Administration.
Critics have warned that the TrumpRx website may not meaningfully lower drug prices for most Americans, as the discounts are only available to the uninsured or those whose insurance does not cover the listed drugs. Those with insurance coverage typically pay lower prices already.
This deal highlights a trend of pharmaceutical companies engaging directly with political administrations to navigate pricing and tariff pressures. Investors will be watching to see if this strategy translates to a meaningful increase in sales volume or if the political alignment creates a backlash from consumers. The next test will be the market's reaction to J&J's stock on Friday and in the coming weeks.
This article is for informational purposes only and does not constitute investment advice.
